

The Genetics Company, Inc. expands Management Team

The Genetics Company today announced the appointments of Dr. Harald Eistetter and Mr. Andreas Ziegler to the positions of Chief Executive Officer and Chief Financial Officer, respectively.

Prof. Dr. Michel Aguet, Chairman of the Board of Directors of The Genetics Company commented: "We are very pleased to welcome Harald and Andreas to our company. Harald's impressive track record within the pharmaceutical industry combined with Andreas' excellent experience in finance make them the ideal persons to further develop this highly dynamic enterprise and to ensure its future success."

Dr. Eistetter obtained his PhD in Genetics from the University of Tübingen (Germany), and held a number of senior research and management positions mainly within the biotech divisions of Byk Gulden, Glaxo and BASF Pharma. Most recently, with BASF Pharma, Dr. Eistetter very successfully managed an internationally operating, fully integrated business unit which further develops and commercializes a world leading molecular biological platform technology.

Mr. Ziegler holds an MBA from the University of Zurich and had worked for two medium-sized Swiss industrial companies before he joined Deloitte & Touche in Zurich. As Audit Manager and Vice Director in Deloitte & Touche's Zurich, New York and Stamford (CT, USA) offices, he was instrumental in the successful management of several corporate finance projects. Mr. Ziegler also is a Swiss federal CPA.

"The Genetics Company has established itself as a world leader in in vivo genetics and functional genomics. This company is among the few that will be able to truly convert DNA sequence and genetic information into both pharmacologically active small molecules and functional proteins in a rapid, reliable and cost-effective manner. This is what makes The Genetics Company so very attractive", Dr. Eistetter and Mr. Ziegler explained their career moves. "We very much are looking forward to the challenges of further growing The Genetics Company to the benefit of its shareholders and customers."

The Genetics Company founded in 1998, has corporate headquarters in Zurich, Switzerland, and research facilities in both Zurich and Lausanne. The company has established a world-leading position in high-throughput in vivo functional genomics using the fruit fly and mouse as model systems. It has compiled powerful technologies to identify and validate novel drug screening targets as well as pharmacologically active small compounds and therapeutic proteins for the treatment of a wide range of diseases. A research alliance has been established with Intervet GmbH (Wiesbaden, Germany), a top 3 company in animal healthcare and a subsidiary of Akzo Nobel, to identify novel targets that may lead to the development of novel anti-parasites.

06-20-2001 / 2,850 characters